Download PDF
Am J Perinatol 2010; 27(5): 421-424
DOI: 10.1055/s-0029-1243370
© Thieme Medical Publishers

Daptomycin Use in a Neonate: Serum Level Monitoring and Outcome

Kosmas Sarafidis1 , Elias Iosifidis2 , Evangelos Gikas3 , Maria Tsivitanidou4 , Vassiliki Drossou-Agakidou1 , Emmanuel Roilides2
  • 11st Department of Neonatology, Aristotle University, Hippokration General Hospital, Thessaloniki, Greece
  • 23rd Department of Pediatrics, Aristotle University, Hippokration General Hospital, Thessaloniki, Greece
  • 3The Goulandris Natural History Museum, GAIA Research Center, Kifissia, Greece
  • 4Department of Microbiology, Hippokration General Hospital, Thessaloniki, Greece
Further Information

Publication History

Publication Date:
10 December 2009 (online)

    Permissions and Reprints

Corrected by:

Daptomycin Use in a Neonate: Serum Level Monitoring and OutcomeAm J Perinatol 2012; 29(10): 843-844
DOI: 10.1055/s-0032-1329394

ABSTRACT

We present a case of successfully treated persistent bacteremia due to Gram-positive bacteria with daptomycin in a preterm neonate. Daptomycin was given at higher doses (6 mg/kg/dose) and shorter intervals (every 12 hours) than those recommended for adults with no adverse events. Peak and trough serum concentrations of daptomycin were 22.9 and 11.6 μg/mL at day 4 as well as 27.3 and 7.9 μg/mL at day 11 after initiation of treatment, respectively.

KEYWORDS

Daptomycin - neonate - drug monitoring - enterococcal bacteremia

REFERENCES

  • 1 Sauermann R, Rothenburger M, Graninger W, Joukhadar C. Daptomycin: a review 4 years after first approval.  Pharmacology. 2008;  81 79-91
    CrossrefPubMedGoogle Scholar
  • 2 Ardura M I, Mejías A, Katz K S, Revell P, McCracken Jr G H, Sánchez P J. Daptomycin therapy for invasive gram-positive bacterial infections in children.  Pediatr Infect Dis J. 2007;  26 1128-1132
    PubMedGoogle Scholar
  • 3 Abdel-Rahman S M, Benziger D P, Jacobs R F, Jafri H S, Hong E F, Kearns G L. Single-dose pharmacokinetics of daptomycin in children with suspected or proved gram-positive infections.  Pediatr Infect Dis J. 2008;  27 330-334
    CrossrefPubMedGoogle Scholar
  • 4 Cohen-Wolkowiez M, Smith P B, Benjamin Jr D K, Fowler Jr V G, Wade K C. Daptomycin use in infants: report of two cases with peak and trough drug concentrations.  J Perinatol. 2008;  28 233-234
    CrossrefPubMedGoogle Scholar
  • 5 Sakoulas G, Golan Y, Lamp K C, Friedrich L V, Russo R. Daptomycin in the treatment of bacteremia.  Am J Med. 2007;  120(10 Suppl 1) S21-S27
    PubMedGoogle Scholar
  • 6 Mohr J F, Friedrich L V, Yankelev S, Lamp K C. Daptomycin for the treatment of enterococcal bacteraemia: results from the Cubicin Outcomes Registry and Experience (CORE).  Int J Antimicrob Agents. 2009;  33 543-548
    CrossrefPubMedGoogle Scholar
  • 7 Dvorchik B, Arbeit R D, Chung J, Liu S, Knebel W, Kastrissios H. Population pharmacokinetics of daptomycin.  Antimicrob Agents Chemother. 2004;  48 2799-2807
    CrossrefPubMedGoogle Scholar
  • 8 Benvenuto M, Benziger D P, Yankelev S, Vigliani G. Pharmacokinetics and tolerability of daptomycin at doses up to 12 milligrams per kilogram of body weight once daily in healthy volunteers.  Antimicrob Agents Chemother. 2006;  50 3245-3249
    CrossrefPubMedGoogle Scholar
  • 9 Castanheira M, Jones R N, Sader H S. Update of the in vitro activity of daptomycin tested against 6710 gram-positive cocci isolated in North America (2006).  Diagn Microbiol Infect Dis. 2008;  61 235-239
    CrossrefPubMedGoogle Scholar
  • 10 Malli E, Spiliopoulou I, Kolonitsiou F et al.. In vitro activity of daptomycin against gram-positive cocci: the first multicentre study in Greece.  Int J Antimicrob Agents. 2008;  32 525-528
    CrossrefPubMedGoogle Scholar

Emmanuel RoilidesM.D. Ph.D. 

Associate Professor, 3rd Department of Pediatrics, Aristotle University

Hippokration General Hospital, Kostantinoupoleos 49, 54642, Thessaloniki, Greece

Email: roilides@med.auth.gr

      >